Piper Jaffray Starts CRISPR Therapeutics (CRSP) at Overweight

November 14, 2016 7:56 AM EST
Get Alerts CRSP Hot Sheet
Price: $20.00 -4.9%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CRSP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with an Overweight rating and a price target of $21.00.

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $17.50 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Piper Jaffray

Add Your Comment